The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a huge mover today! About 717,596 shares traded hands or 134.32% up from the average. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has risen 18.55% since February 29, 2016 and is uptrending. It has outperformed by 6.33% the S&P500.
The move comes after 5 months negative chart setup for the $122.97 million company. It was reported on Oct, 4 by Barchart.com. We have $4.63 PT which if reached, will make NASDAQ:DRNA worth $12.30M less.
Analysts await Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to report earnings on November, 8. They expect $-0.86 earnings per share, down 4.88% or $0.04 from last year’s $-0.82 per share. After $-0.75 actual earnings per share reported by Dicerna Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 14.67% negative EPS growth.
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Ratings Coverage
Out of 4 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Dicerna Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Monday, August 15 with “Neutral” rating. The firm has “Buy” rating given on Tuesday, May 10 by Stifel Nicolaus. The rating was maintained by Stifel Nicolaus on Wednesday, November 11 with “Buy”. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) earned “Neutral” rating by Chardan Capital Markets on Thursday, June 30. The stock has “Buy” rating given by Stifel Nicolaus on Monday, August 10. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, June 30. The firm has “Outperform” rating by Cowen & Co given on Tuesday, September 8.
According to Zacks Investment Research, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.76 in Q2 2016. Its down 0.24, from 1 in 2016Q1. The ratio turned negative, as 15 funds sold all Dicerna Pharmaceuticals Inc shares owned while 18 reduced positions. 11 funds bought stakes while 14 increased positions. They now own 12.70 million shares or 13.90% less from 14.75 million shares in 2016Q1.
Blackrock Institutional Trust Co Na holds 0% or 80,368 shares in its portfolio. Manufacturers Life Insur The has 0% invested in the company for 671 shares. Northern Tru accumulated 0% or 36,463 shares. Ra Management Ltd Liability Corp, a Massachusetts-based fund reported 2.43M shares. D E Shaw Co holds 0% or 74,791 shares in its portfolio. Blackrock Limited last reported 0% of its portfolio in the stock. Oxford Asset Mngmt accumulated 286,413 shares or 0.04% of the stock. Tower Rech Capital Limited Liability Co (Trc) accumulated 0% or 1,220 shares. Lmr Limited Liability Partnership owns 11,757 shares or 0.01% of their US portfolio. Bourgeon Mgmt Ltd Llc owns 20,000 shares or 0.04% of their US portfolio. Jane Street Grp Ltd Liability has invested 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Alpine Prtn Vi Lc last reported 0.03% of its portfolio in the stock. Deutsche State Bank Ag accumulated 68,918 shares or 0% of the stock. Barclays Public Limited Company reported 1,842 shares or 0% of all its holdings. Jpmorgan Chase & Co owns 20,142 shares or 0% of their US portfolio.
Insider Transactions: Since May 12, 2016, the stock had 1 buying transaction, and 0 sales for $16,434 net activity. Weissman James B had bought 5,000 shares worth $16,434 on Thursday, May 12.
Another recent and important Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) news was published by Finance.Yahoo.com which published an article titled: “Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%” on September 22, 2016.
DRNA Company Profile
Dicerna Pharmaceuticals, Inc., incorporated on October 24, 2006, is a ribonucleic acid (RNA) interference biopharmaceutical company. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Firm uses its RNAi technology platform to build a pipeline in these therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.